Research advances in gene polymorphisms in biological pathways of drugs for asthma.
- Author:
Dan-Dan GUO
1
;
Xiang-Rong ZHENG
Author Information
1. Department of Pediatrics, Xiangya Hospital, Central South University, Changsha 410008, China. zxr_168@126.com.
- Publication Type:Journal Article
- MeSH:
Adrenergic beta-2 Receptor Agonists;
therapeutic use;
Asthma;
drug therapy;
genetics;
Glucocorticoids;
therapeutic use;
Leukotrienes;
genetics;
therapeutic use;
Metabolic Networks and Pathways;
Pharmacogenetics;
Polymorphism, Single Nucleotide;
Precision Medicine
- From:
Chinese Journal of Contemporary Pediatrics
2016;18(6):567-573
- CountryChina
- Language:Chinese
-
Abstract:
The studies on gene polymorphisms in biological pathways of the drugs for the treatment of asthma refer to the studies in which pharmacogenetic methods, such as genome-wide association studies, candidate gene studies, genome sequencing, admixture mapping analysis, and linkage disequilibrium, are used to identify, determine, and repeatedly validate the effect of one or more single nucleotide polymorphisms on the efficacy of drugs. This can provide therapeutic strategies with optimal benefits, least side effects, and lowest costs to patients with asthma, and thus realize individualized medicine. The common drugs for asthma are β2 receptor agonists, glucocorticoids, and leukotriene modifiers. This article reviews the research achievements in polymorphisms in biological pathways of the common drugs for asthma, hoping to provide guidance for pharmacogenetic studies on asthma in future and realize individualized medicine for patients with asthma soon.
